Skip to main content Skip to section navigation Skip to footer
Sutro Logo high res
  • Who We Are
    • About Sutro
    • Leadership
      • Leadership Team
      • Board of Directors
      • Scientific Advisory Board
      • Clinical Advisory Board
    • Collaborations
  • Proprietary Platform
  • Pipeline
    • Overview
    • Scientific Publications
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Financials
    • Stock Data
    • Governance
    • IR Resources
  • Careers
    • The Way We Work
    • DEIB
    • Sustainability
    • Internships
    • Philanthropy
      • Employee Engagement
  • Contact Us

Press Releases

Investors

Investors

  • Overview
  • Press Releases
  • Events & Presentations
  • Financials
    • Financial Results
    • SEC Filings
    • Annual Reports
  • Stock Data
    • Quote & Chart
    • Historical Data
    • Analyst Coverage
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • IR Resources
    • FAQ
    • Email Alerts
    • Contact
Nov 2, 2022 7:00 am EDT
Sutro Biopharma to Participate in Upcoming Investor Conferences
Oct 24, 2022 7:00 am EDT
Sutro Biopharma Announces Departure of Chief Medical Officer
Sep 1, 2022 7:00 am EDT
Sutro Biopharma to Present at the 2022 Wells Fargo Healthcare Conference
Aug 19, 2022 4:01 pm EDT
Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 8, 2022 4:30 pm EDT
Sutro Biopharma Reports Second Quarter 2022 Financial Results, Business Highlights and Anticipated Milestones
Aug 3, 2022 7:00 am EDT
Sutro Biopharma to Present at the 2022 Wedbush PacGrow Healthcare Conference
Jul 26, 2022 4:01 pm EDT
Sutro Biopharma Achieves “First in Human” Milestone in Cytokine Derivatives Collaboration with Merck
Jul 12, 2022 7:00 am EDT
Sutro Biopharma Announces Virtual Deep Dive Research Forum: Next-Gen Innovations in ADCs
Jun 27, 2022 7:31 pm EDT
Astellas and Sutro Biopharma Announce Worldwide Strategic Collaboration to Advance Novel Immunostimulatory Antibody-Drug Conjugates (iADCs)
Jun 3, 2022 4:01 pm EDT
Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  • Previous Pagearrow_back
  • Page 1
  • …
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • Page 11
  • Page 12
  • …
  • Page 23
  • Next Pagearrow_forward
rss_feed News RSS
  • emailEmail Alerts
  • contact_pageContacts
  • rss_feedRSS News Feed
Sutro Biopharma Corporate Site

Dedicated to patients
and changing the future of oncology

  • Follow
  • Follow
  • Follow
  • Follow

Follow us on social media

© 2025 Sutro Biopharma, Inc.
South San Francisco, California, U.S.A.

SITE MAP | PRIVACY POLICY | EMAIL ALERTS | CONTACT US | VISITOR GUIDE

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in .

Sutro Biopharma, Inc.
Powered by GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.